KOREA WHO
-
-
-
CEO of Samyang Biopharm
Kim Kyung-jin
15 Years at Roche, Advancing SENS Drug Platform
-
Last Updated on Apr 28, 2026
-
CEO of Samyang Biopharm
Life Summary
Kim Kyung-jin is the CEO of Samyang Biopharm.
He is focusing on advancing the proprietary drug delivery platform SENS while accelerating expansion into the global market with key products such as sutures and anticancer drugs.
He was born on July 29, 1963.
He graduated from Sogang University with a degree in chemistry, earned a master’s degree in chemistry from Sogang University Graduate School, and received a Ph.D. in organic chemistry from Texas A&M University in the United States.
He worked as a researcher for 15 years at the Nutley Research Center of Swiss global pharmaceutical company Roche in the United States.
He later moved to ST Pharm, where he served as head of the Synthetic Research Division 1 and head of the research institute. He was appointed CEO in 2017.
He joined the Samyang Group as head of the Biopharm Group under Samyang Biopharm (then the pharmaceutical and bio division of Samyang Holdings) and was appointed co-CEO of Samyang Holdings in March 2025.
In November 2025, he assumed the role of CEO of Samyang Biopharm, which had been spun off again.
He has a background as a researcher at a global big pharma company.
He is decisive.
#SamyangBiopharm #KimKyungjin #Biopharmaceuticals #DrugDeliveryPlatform #SENS #GlobalPharma #Roche #STPharm #AnticancerDrugs #BiotechLeadership
He is focusing on advancing the proprietary drug delivery platform SENS while accelerating expansion into the global market with key products such as sutures and anticancer drugs.
He was born on July 29, 1963.
He graduated from Sogang University with a degree in chemistry, earned a master’s degree in chemistry from Sogang University Graduate School, and received a Ph.D. in organic chemistry from Texas A&M University in the United States.
He worked as a researcher for 15 years at the Nutley Research Center of Swiss global pharmaceutical company Roche in the United States.
He later moved to ST Pharm, where he served as head of the Synthetic Research Division 1 and head of the research institute. He was appointed CEO in 2017.
He joined the Samyang Group as head of the Biopharm Group under Samyang Biopharm (then the pharmaceutical and bio division of Samyang Holdings) and was appointed co-CEO of Samyang Holdings in March 2025.
In November 2025, he assumed the role of CEO of Samyang Biopharm, which had been spun off again.
He has a background as a researcher at a global big pharma company.
He is decisive.
#SamyangBiopharm #KimKyungjin #Biopharmaceuticals #DrugDeliveryPlatform #SENS #GlobalPharma #Roche #STPharm #AnticancerDrugs #BiotechLeadership